

* * * * * Welcome to STN International * * * * *

- NEWS 1 JUN 26 COMPENDEX - New Fields for Author Identifier and URL
- NEWS 2 JUN 30 Numeric Property Search Added to USPATFULL and USPAT2
- NEWS 3 AUG 5 Chemical and Technology Databases RAPRA, CEABA,
and TEMA Add Numeric Property Search
- NEWS 4 OCT 7 EP Appeal Data from European Patent Register Added to
INPADOCDB and INPAFAMDB
- NEWS 5 NOV 15 Enhanced INPADOCDB and INPAFAMDB Files
- NEWS 6 NOV 23 Claims Access in CA/CAplus: WIPO, United States, and China
for 1999 - Present.
- NEWS 7 DEC 1 Engineering Flagship Database Inspec Reaches
Milestone 20 Million Total Records
- NEWS 8 DEC 1 Full-Text Patent Documents from German Democratic
Republic Added to DEFULL
- NEWS 9 FEB 7 Patent Status Indicators in CA/CAplus
- NEWS 10 FEB 16 ReaxysFileSub and companion bibliographic
database ReaxysFileBib new on STNnext(R)
- NEWS 11 APR 12 New Version of the EPFULL (European Patent Full Text
Database) Launched on STN
- NEWS 12 APR 12 Analytical Abstracts Enhancements Increase Value to Users
- NEWS 13 APR 13 INSPEC Reload Features Numeric Property Searching, Cited
References and DOIs
- NEWS 14 MAY 10 May 2021 Update to Emtree(R) Now Available on STN
- NEWS 15 SEP 6 New Russian Patent Full Text Database RUFULL Launched on STN
- NEWS 16 SEP 6 NTIS Reload on STNnext Resumes Updating; Introduces Numeric
Property Searching and SLART Improvements
- NEWS 17 SEP 11 September 2021 Update to Emtree(R) Now Available on STN
- NEWS 18 OCT 4 MARPAT(R) Enhanced with Patent Status Data

- NEWS HOURS STN Operating Hours Plus Help Desk Availability
- NEWS LOGIN Welcome Banner and News Items
- NEWS TRAINING Find instructor-led and self-directed training opportunities

Enter NEWS followed by the item number or name to see news on that specific topic.

For pricing information enter HELP PRICE or HELP COST at any arrow prompt.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

Access the latest version of STN.

Log into STNnext with your STN login ID at <https://www.stn.org>

STNnext is updated frequently. To see the latest STNnext Release Notes, click <https://www.stn.org/help/stnext/ReleaseNotes.htm>

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:01:37 ON 04 NOV 2021
ENTER COST CENTER (NONE):fil caplus

CHARGED TO COST=FIL CAPLUS

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:02:30 ON 04 NOV 2021
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
COPYRIGHT (C) 2021 AMERICAN CHEMICAL SOCIETY (ACS)
CHARGED TO COST=FIL CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Nov 2021 VOL 176 ISS 8
FILE LAST UPDATED: 3 Nov 2021 (20211103/ED)

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s voswickel r?/au

L1 0 VOSWICKEL R?/AU

=> s voswinckel r?/au

L2 73 VOSWINCKEL R?/AU

=> s l2 and treprostiniil/ti

L3 267 TREPROSTINIL/TI
8 L2 AND TREPROSTINIL/TI

=> d scan l3

L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
CC 1-8 (Pharmacology)
TI Addition of inhaled [treprostiniil](#) to oral therapy for pulmonary arterial

hypertension

ST pulmonary arterial hypertension treprostinil sodium antihypertensive
sildenafil bosentan exercise

IT Antihypertensives
Exercise
Human
Inhalation drug delivery systems
Oral drug delivery systems
Pulmonary hypertension
(addn. of inhaled treprostinil sodium to oral therapy with either
bosentan or sildenafil was safe, well tolerated, improved exercise
capacity and quality of life in patient with pulmonary arterial
hypertension)

IT 686719-75-5, N-Terminal pro-brain natriuretic peptide
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(addn. of inhaled treprostinil sodium to oral therapy with either
bosentan or sildenafil improved N-terminal pro-brain natriuretic
peptide level in patient with pulmonary arterial hypertension)

IT 139755-83-2, Sildenafil 147536-97-8, Bosentan 289480-64-4,
Treprostinil sodium
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(addn. of inhaled treprostinil sodium to oral therapy with either
bosentan or sildenafil was safe, well tolerated, improved exercise
capacity and quality of life in patient with pulmonary arterial
hypertension)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8

L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN

IPCI A61K0031-557 [I]; A61K0009-72 [I]; A61K0009-12 [I]; A61K0031-557 [I];
A61K0031-557 [I]; A61K0009-12 [I]; A61K0009-12 [I]; A61K0009-72 [I];
A61K0009-72 [I]

IPCR A61K0031-557 [I]; A61K0009-12 [I]; A61K0009-72 [I]

CPCI A61K0009-008 [I]; A61K0031-192 [I]; A61K0031-557 [I]; A61P0009-00 [I];
A61P0009-12 [I]; A61P0011-00 [I]; A61P0043-00 [I]; A61K0009-00 [I];
A61K0009-12 [I]; A61K0009-0078 [I]

ECLA A61K0031-557; A61K0009-00M20B6; A61K0031-557; A61K0009-00M20B6

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 4

TI Inhalant containing **treprostinil** and its derivatives in a metered dose
inhaler

ST inhalant treprostinil deriv metered dose inhaler

IT Toxicity
(acute; inhalant contg. treprostinil and derivs. in metered dose
inhaler)

IT Circulation
Dizziness
Headache
Human
Inhalation drug delivery systems
Medical inhalers
Nausea
(inhalant contg. treprostinil and derivs. in metered dose inhaler)

IT 81846-19-7, Treprostinil 289480-64-4, Treprostinil sodium
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant contg. treprostinil and derivs. in metered dose inhaler)

IT 21829-25-4, Nifedipine 35121-78-9, Prostacyclin 42399-41-7, Diltiazem 78919-13-8, Iloprost 81846-19-7D, Treprostinil, derivs. 88150-42-9, Amlodipine 88430-50-6, Beraprost 139755-83-2, Sildenafil 147536-97-8, Bosentan 171596-29-5, Tadalafil 177036-94-1, Ambrisentan 184036-34-8, Sitaxsentan 224785-90-4, Vardenafil

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalant contg. treprostinil and derivs. in metered dose inhaler)

L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
CC 1-0 (Pharmacology)
TI Inhaled **treprostinil**: a therapeutic review
ST review antihypertensive inhaled treprostinil pulmonary arterial hypertension
IT Antihypertensives
Bioavailability
Cardiovascular system
Human
Inhalation drug delivery systems
Pulmonary hypertension
(therapeutic review of inhaled treprostinil)

IT 81846-19-7, Treprostinil
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(therapeutic review of inhaled treprostinil)

L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
CC 1-9 (Pharmacology)
Section cross-reference(s): 63
TI Metered dose inhaler delivery of **treprostinil** for the treatment of pulmonary hypertension
ST metered dose inhaler treprostinil antihypertensive pulmonary vasodilator lung hypertension
IT Medical inhalers
(Respimat; metered dose inhaler delivery of treprostinil for treatment of pulmonary hypertension)
IT Human
Inhalation drug delivery systems
Pulmonary antihypertensives
Pulmonary hypertension
Vascular resistance
(metered dose inhaler delivery of treprostinil for treatment of pulmonary hypertension)

IT Vasodilators
(pulmonary; metered dose inhaler delivery of treprostinil for treatment of pulmonary hypertension)

IT 289480-64-4, Treprostinil sodium
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Respimat; metered dose inhaler delivery of treprostinil for treatment of pulmonary hypertension)

L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
CC 1-8 (Pharmacology)
TI Favorable effects of inhaled **treprostinil** in severe pulmonary hypertension. Results from randomized controlled pilot studies

ST treprostinil iloprost pulmonary hypertension pharmacokinetics vasodilator antihypertensive

IT Blood pressure
(inhaled treprostinil and iloprost were comparable in their ability to decrease pulmonary arterial pressure in severe pulmonary hypertension patient)

IT Vascular resistance
(inhaled treprostinil and iloprost were comparable in their ability to decrease pulmonary vascular resistance in severe pulmonary hypertension patient)

IT Antihypertensives
Human
Pulmonary hypertension
Vasodilators
(inhaled treprostinil exerted sustained pulmonary vasodilation compared to iloprost and was well tolerated at low dose with reduced inhalation time in severe pulmonary hypertension patient)

IT Pharmacokinetics
(inhaled treprostinil revealed acceptable pharmacokinetics characteristic in severe pulmonary hypertension patient)

IT Cardiac contraction
(systemic arterial pressure was unaffected by treprostinil while it was decreased by iloprost in severe pulmonary hypertension patient)

IT 81846-19-7, Treprostinil
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhaled treprostinil exerted sustained pulmonary vasodilation compared to iloprost and was well tolerated at low dose with reduced inhalation time in severe pulmonary hypertension patient)

IT 78919-13-8, Iloprost
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhaled treprostinil exerted sustained pulmonary vasodilation compared to iloprost and was well tolerated at low dose with reduced inhalation time in severe pulmonary hypertension patient)

IT 7782-44-7, Oxygen, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neither treprostinil nor iloprost affected pulmonary gas exchange in severe pulmonary hypertension patient)

L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN

CC 1-12 (Pharmacology)

TI **Treprostinil** inhibits the adhesion and differentiation of fibrocytes via the cyclic adenosine monophosphate-dependent and Ras-proximate protein-dependent inactivation of extracellular regulated kinase

ST treprostinil antihypertensive cAMP Ras ERK fibrocyte adhesion differentiation

IT Antihypertensives
Cell adhesion
Cell differentiation
Fibroblast
Hypoxia
Mononuclear leukocyte
Phosphorylation
Pulmonary hypertension
Signal transduction

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.